Tag: HR-Positive Breast Cancer

Home / HR-Positive Breast Cancer

Categories

Inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer

 On October 10, 2024, the Food and Drug Administration authorized inavolisib (Itovebi, Genentech, Inc.) in conjunction with palbociclib and fulvestrant for adults diagnosed with endocrine-resistant, ...
hr-positive-breast-cancer

Scan the code